Form 8-K Summary
Registrant: MedTech Acquisition Corporation (proposed post-combination name: TriSalus Life Sciences, Inc.)
Report date: August 2, 2023. The filing was submitted under Item 8.01, Other Events, primarily to supplement the definitive proxy statement/prospectus regarding the proposed business combination with TriSalus Life Sciences, Inc.
Business Context and Transaction
MTAC previously agreed to merge its wholly owned subsidiary, MTAC Merger Sub, Inc., with TriSalus. TriSalus would survive as a wholly owned subsidiary of MTAC, and TriSalus equity holders would receive MTAC common stock. Upon closing, MTAC is expected to be renamed TriSalus Life Sciences, Inc.
The SEC declared the related Form S-4 registration statement effective on July 18, 2023. The special stockholder meeting was scheduled for August 2, 2023, to vote on the merger and related proposals. This filing does not report the meeting results or completion of the business combination.
Financial Metrics and Liquidity
The filing does not provide current-period revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It also does not report a completed financing or updated cash balance.
Completion of the business combination remains subject to, among other matters, stockholder approval, minimum cash requirements after redemptions, regulatory approvals, and the concurrent private placement of Series A Convertible Stock.
Material Changes and Clinical Program Update
- On July 31, 2023, TriSalus received written FDA responses regarding a Type B meeting request for the PERIO-01 clinical program.
- The FDA stated that preliminary data suggested a tolerable safety profile for SD-101 delivered using TriSalus’s pressure-enabled drug delivery method in combination with systemic checkpoint inhibition in metastatic uveal melanoma patients.
- The FDA raised no concerns regarding delivery of SD-101 through the TriNav device but requested additional exploration of the optimal SD-101 dose before proceeding to a registrational trial.
- TriSalus plans a 40- to 50-patient study to generate additional efficacy and dose-optimization data. It expected to initiate a Phase 2 trial in 2023, subject to regulatory interactions, enrollment, site conditions, and other external factors.
- TriSalus expected more mature Phase 1 efficacy data across multiple SD-101 doses in the second half of 2023.
- Following the FDA feedback, a potential new drug application for SD-101 in uveal melanoma with liver metastases is likely to occur beyond 2025, pending Phase 2 efficacy and dose-optimization results.
- TriSalus was also considering a separate study of SD-101 combined with Y90 radioembolization for advanced second-line and later hepatocellular carcinoma. Prioritization was expected to depend on data available in the second half of 2023.
Outlook, Risks, and Contingencies
Clinical development timelines and regulatory milestones are uncertain and may change based on FDA interactions, patient enrollment, clinical-site operations, external events, and trial results. The filing’s forward-looking statements also depend on the timely completion of the business combination and related financing.
- The merger may not close, may be delayed, or may fail to satisfy its conditions, including stockholder approval, minimum cash requirements, and regulatory approvals.
- Redemptions by public stockholders could reduce available capital, and the Series A Convertible Stock private placement may not close.
- TriSalus may require additional financing to support operations and development programs.
- Clinical trials may not produce favorable efficacy or safety results, and regulatory submissions or approvals may be delayed or not obtained.
- Other risks include potential legal proceedings, Nasdaq listing requirements, reimbursement changes, transaction costs, alternative proposals, disruption to TriSalus’s operations, and failure to realize expected transaction benefits.
Key Facts for Investors to Verify
- Whether MTAC stockholders approved the business combination and whether the transaction subsequently closed.
- The amount of cash available after stockholder redemptions and whether the minimum cash condition was satisfied.
- Whether the Series A Convertible Stock private placement was completed and its effect on capitalization and liquidity.
- Updated PERIO-01 enrollment, dose-optimization results, efficacy data, and the timing of the Phase 2 study.
- Whether the FDA’s feedback changes the clinical development path or the timing of any potential SD-101 application beyond 2025.
- Current financial statements, cash runway, debt, financing needs, and post-transaction ownership, which are not provided in this filing.